Funding for this research was provided by:
Higher Committee for Education Development in Iraq (NA)
European Cooperation in Science and Technology (BM1406)
National Institutes of Health (DP1GM114862, R01EY022238, R01EY024068)
John Templeton Foundation
National Science Centre, Poland (DEC-2013/11/B/NZ3/01573)
DuPont Guerry, III Professorship
Received: 26 March 2018
Accepted: 28 March 2018
First Online: 11 April 2018
: All animal experiments were performed in accordance with the Principles of Laboratory Animal Care (NIH publication No. 86–23, revised 1985) and approvals of the Institutional Ethical Review Board and the Home Office UK (70/7479).
: Not Applicable.
: J.A. is a cofounder of iVeena Holdings, iVeena Delivery Systems and Inflammasome Therapeutics and has been a consultant for Allergan, Biogen, Olix Pharmaceuticals, and Saksin LifeSciences in a capacity unrelated to this work. J.A. and K.A. are named as inventors on patent applications on macular degeneration filed by the University of Kentucky or the University of Virginia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.